PDF(Pubmed)
Abstract：
UNASSIGNED: Primary ovarian insufficiency (POI) is characterized by the development of hypergonadotropic hypogonadism before 40 years of age and leads to intractable infertility. Although in vitro fertilization and embryo transfer with donated eggs enables pregnancy, not a few patients desire pregnancy using their oocytes. However, follicular development is rare and unpredictable in patients with POI. Thus, there is a need for treatments that promote the development of residual follicles and methods to accurately predict infrequent ovulation.
UNASSIGNED: This review discusses the effects of various treatments for obtaining eggs from POI patients. Furthermore, this study focused a potential marker for predicting follicular growth in patients with POI.
UNASSIGNED: Different treatments such as hormone-replacement therapy, dehydroepiandrosterone supplementation, platelet-rich plasma injection, and in vitro activation have shown varying degrees of effectiveness in retrieving oocytes from patients with POI. To predict follicle development in the cycle, elevated serum estradiol and reduced follicle-stimulating hormone (FSH) levels are important. However, these markers are not always reliable under continuous estradiol-replacement therapy. As a novel marker for predicting follicle growth, serum anti-Müllerian hormone (AMH) levels, measured using the picoAMH enzyme-linked immunosorbent assay, were found to predict follicle growth in patients and the cycle.
UNASSIGNED: This review highlights the challenges and available interventions for achieving pregnancy using a patient\'s oocytes in cases of POI. We believe that a combination of currently available treatments and prediction methods is the best strategy to enable patients with POI to conceive using their own eggs. Although AMH levels may predict follicle growth, further research is necessary to improve the chances of successful follicular development and conception in patients with POI.
UNASSIGNED: This review discusses the effects of various treatments for obtaining eggs from POI patients. Furthermore, this study focused a potential marker for predicting follicular growth in patients with POI.
UNASSIGNED: Different treatments such as hormone-replacement therapy, dehydroepiandrosterone supplementation, platelet-rich plasma injection, and in vitro activation have shown varying degrees of effectiveness in retrieving oocytes from patients with POI. To predict follicle development in the cycle, elevated serum estradiol and reduced follicle-stimulating hormone (FSH) levels are important. However, these markers are not always reliable under continuous estradiol-replacement therapy. As a novel marker for predicting follicle growth, serum anti-Müllerian hormone (AMH) levels, measured using the picoAMH enzyme-linked immunosorbent assay, were found to predict follicle growth in patients and the cycle.
UNASSIGNED: This review highlights the challenges and available interventions for achieving pregnancy using a patient\'s oocytes in cases of POI. We believe that a combination of currently available treatments and prediction methods is the best strategy to enable patients with POI to conceive using their own eggs. Although AMH levels may predict follicle growth, further research is necessary to improve the chances of successful follicular development and conception in patients with POI.
摘要：
■原发性卵巢功能不全（POI）的特征是在40岁之前发生高促性腺激素性腺功能减退症，并导致顽固性不孕。尽管使用捐赠的卵子进行体外受精和胚胎移植可以怀孕，不少患者希望使用卵母细胞怀孕。然而,POI患者的卵泡发育很少且不可预测。因此，需要促进残余卵泡发育的治疗方法和准确预测罕见排卵的方法.
■这篇综述讨论了从POI患者获得卵子的各种治疗方法的效果。此外，这项研究集中了预测POI患者卵泡生长的潜在标志物.
■不同的治疗方法，如激素替代疗法，脱氢表雄酮补充，富血小板血浆注射液,和体外激活在从POI患者中获取卵母细胞方面显示出不同程度的有效性。为了预测周期中的卵泡发育，血清雌二醇水平升高和卵泡刺激素(FSH)水平降低是重要的.然而,在持续的雌二醇替代疗法下,这些标志物并不总是可靠的.作为预测卵泡生长的新标记，血清抗苗勒管激素（AMH）水平，使用picoAMH酶联免疫吸附测定法测量，被发现可以预测患者的卵泡生长和周期。
■这篇综述强调了在POI病例中使用患者的卵母细胞实现妊娠的挑战和可用的干预措施。我们认为，结合目前可用的治疗方法和预测方法是使POI患者能够使用自己的卵子受孕的最佳策略。虽然AMH水平可以预测卵泡的生长，需要进一步研究以提高POI患者成功卵泡发育和受孕的机会。
■这篇综述讨论了从POI患者获得卵子的各种治疗方法的效果。此外，这项研究集中了预测POI患者卵泡生长的潜在标志物.
■不同的治疗方法，如激素替代疗法，脱氢表雄酮补充，富血小板血浆注射液,和体外激活在从POI患者中获取卵母细胞方面显示出不同程度的有效性。为了预测周期中的卵泡发育，血清雌二醇水平升高和卵泡刺激素(FSH)水平降低是重要的.然而,在持续的雌二醇替代疗法下,这些标志物并不总是可靠的.作为预测卵泡生长的新标记，血清抗苗勒管激素（AMH）水平，使用picoAMH酶联免疫吸附测定法测量，被发现可以预测患者的卵泡生长和周期。
■这篇综述强调了在POI病例中使用患者的卵母细胞实现妊娠的挑战和可用的干预措施。我们认为，结合目前可用的治疗方法和预测方法是使POI患者能够使用自己的卵子受孕的最佳策略。虽然AMH水平可以预测卵泡的生长，需要进一步研究以提高POI患者成功卵泡发育和受孕的机会。
